Claims for Patent: 6,825,035

Summary for Patent: 6,825,035

Title:	Compositions and methods for modulating expression within smooth muscle cells
Abstract:	The present invention relates to promoters, enhancers and other regulatory elements that direct expression within SMC, comprising nucleotide sequences from the 5\' regulatory region and the first intron, and transcriptionally active fragments thereof, that control expression of an SM .alpha.-A. Specifically provided are expression vectors, host cells and transgenic animals wherein an SM .alpha.-A regulatory region is capable of controlling expression of a heterologous gene, over-expressing an endogenous SMC gene or an inhibitor of a pathological process or knocking out expression of a specific gene believed to be important for an SM-related disease in SMC. The invention also relates to methods for using said vectors, cells and animals for screening candidate molecules for agonists and antagonists of disorders involving SMC. The invention further relates to compositions and methods for modulating expression of compounds within SMC, and to screening compounds that modulate expression within SMC. Methods for using the molecules and compounds identified by the screening assays for therapeutic treatments also are provided.
Inventor(s):	Owens; Gary K. (Earlysville, VA), Mack; Christopher (Chapel Hill, NC), Blank; Randall (Charlottesville, VA)
Assignee:	Setagon, Inc. (Charlottesville, VA)
Application Number:	09/807,757
Patent Claims:	1. An isolated polynucleotide comprising nucleotides 3331-3656, 3495-3599 or 3421-3548 of SEQ ID NO: 1 spliced downstream of nucleotides 1-2558 of SEQ ID NO: 1. 2. An isolated polynucleotide comprising a smooth muscle (SM) .alpha.-A promoter/enhancer in operable association with a heterologous polynucleotide, wherein the promoter/enhancer comprises sufficient sequence from the first intron of the SM .alpha.-A gene to confer smooth muscle cell-specific expression in vivo and wherein the promoter/enhancer comprises a nucleic acid that hybridizes to the complement of SEQ ID NO:1 when DNA comprising the complement of SEQ ID NO:1 is hybridized in 0.5 M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65.degree. C., and washed in 0.1.times.SSC/0.1% SDS at 68.degree. C. 3. The isolated polynucleotide of claim 2, wherein the sequence from the first intron comprises the rat AP1-like, Int CArG and GATA elements, wherein the AP1-like element comprises SEQ ID NO:26; the Int CArG element comprises SEQ ID NO:16; and the GATA element comprises SEQ ID NO:31. 4. The isolated polynucleotide of claim 2, wherein the sequence from the first intron comprises SEQ ID NO:8. 5. The isolated polynucleotide of claim 2, wherein the promoter/enhancer comprises the CArG B and CArG A elements depicted in SEQ ID NO:15 and SEQ ID NO:14, respectively. 6. The isolated polynucleotide of claim 2, wherein the promoter/enhancer comprises the sequence depicted in SEQ ID NO:4. 7. A vector comprising the polynucleotide of claim 2. 8. An isolated genetically-engineered host cell comprising a polynucleotide comprising a SM .alpha.-A promoter/enhancer in operable association with a heterologous polynucleotide, wherein the promoter/enhancer comprises sufficient sequence from the first intron of the SM .alpha.-A gene to confer smooth muscle cell-specific expression in vivo and wherein the promoter/enhancer comprises a nucleic acid that hybridizes to the complement of SEQ ID NO:1 when DNA comprising the complement of SEQ m NO:1 is hybridized in 0.5 M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65.degree. C., and washed in 0.1.times.SSC/0.1% SDS at 68.degree. C. 9. The host cell of claim 8, wherein the sequence from the first intron comprises the rat AP1-like, Int CArG and GATA elements wherein the AP1-like element comprises SEQ ID NO:26; the Int CArG element comprises SEQ ID NO:16; and the GATA element comprises SEQ ID NO:31. 10. The host cell of claim 8, wherein the promoter/enhancer comprises the nucleotide sequence of SEQ ID NO:1. 11. The host cell of claim 8, wherein the sequence from the first intron comprises SEQ ID NO:8. 12. The host cell of claim 8, wherein the promoter/enhancer comprises the CArG B and CArG A elements depicted in SEQ ID NO:15 and SEQ ID NO:14, respectively. 13. The host cell of claim 8, wherein the promoter/enhancer comprises the sequence depicted in SEQ ID NO:4. 14. The isolated polynucleotide of claim 2, wherein the promoter/enhancer comprises nucleotides 1-2605, 2011-2605, 2011-5342, 3331-3656, 3421-3548 or 3495-3599 of SEQ ID NO:1. 15. The isolated polynucleotide of claim 2, wherein the promoter/enhancer comprises the nucleotide sequence of SEQ ID NO:1.

Details for Patent 6,825,035

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-10-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-10-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-10-23